*November 2020*
Neratinib (Nerlynx) showcased early activity when used in patients with metastatic non–small cell lung cancer (NSCLC) who harbor EGFR exon 18 mutations, according to interim data from the phase 2 SUMMIT trial.1
Results demonstrated that among 10 evaluable patients who received the EGFR inhibitor, 60% (n = 6) had a partial response (PR), with 40% (n = 4) of patients experiencing a confirmed PR. Moreover, 80% (n = 8) of patients derived clinical benefit with neratinib; this was defined as a confirmed complete response, PR, or stable disease for at least 16 weeks. The median duration of response (DOR) with the agent was 7.5 months, while the median progression-free survival (PFS) was 9.1 months. Read more.
